Novel copper–phenothiazine–amino acid complexes exhibit selective anticancer activity via induction of apoptosis and cell cycle arrest in HepG2 cells
Naunyn-Schmiedeberg's Archives of Pharmacology · 28.07.2026
DOI: 10.1007/s00210-026-05745-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 28.07.2026. Verfasst von Sally M Tamim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Program, Faculty of Science, Cairo University, Giza, 12613, Egypt. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Phenothiazine derivatives have gained increasing attention as potential anticancer agents, while copper-based complexes represent promising cancer therapeutic candidates due to their redox activity, coordination versatility, and biological compatibility. In this study, five novel ternary copper(II) complexes were synthesized by combining phenothiazine derivatives with amino acids as secondary ligands to enhance structural diversity, solubility, and cellular uptake. The aim was to investigate their cytotoxic potency, selectivity, and underlying molecular mechanisms against human cancer cell lines, with a particular focus on hepatocellular carcinoma. The five copper(II) complexes were synthesized by combining phenothiazine derivatives-promazine (Prom) and triflupromazine (TFP)-with biologically relevant amino acids (methionine, tryptophan, tyrosine, and serine) as secondary ligands. Using MTT assays, the synthesized complexes [Cu(Prom)(Meth)Cl], [Cu(Prom)(Tryp)Cl]H2O, [Cu(Prom)(Tyr)Cl], [Cu(Prom)(Ser)Cl], and [Cu(TFP)(Ser)Cl] were assessed for their in vitro anticancer efficacy against five human cancer cell lines. Among them, [Cu(TFP)(Ser)Cl] exhibited the highest cytotoxic potency and selectivity toward HepG2 liver cancer cells, with an IC50 value of 15.15 µg/mL. Mechanistic studies revealed that this complex induces apoptosis, cell cycle arrest at G2/M phase, and autophagy, as confirmed by flow cytometric analysis. Gene expression analysis showed significant downregulation of the antiapoptotic BCL2 gene, marked upregulation of the autophagy marker LC3, and moderate upregulation of CDK4. These results were confirmed by molecular docking experiments, which revealed advantageous interactions with proteins involved in cell cycle regulation and apoptosis. These results highlight phenothiazine-copper-amino acid complexes as promising anticancer agents and identify [Cu(TFP)(Ser)Cl] as a potential candidate for hepatocellular carcinoma therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biotechnology Program, Faculty of Science, Cairo University, Giza, 12613, Egypt.
- Department of Zoology, Faculty of Science, Cairo University, Giza, 12613, Egypt. isherif@cu.edu.eg.
- Chemistry Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Zitieren
APA
Tamim, S. M., Zayat, E. E., Ibrahim, S. A., & Shoukry, A. A. (2026). Novel copper–phenothiazine–amino acid complexes exhibit selective anticancer activity via induction of apoptosis and cell cycle arrest in HepG2 cells. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05745-4
Vancouver
Tamim SM, Zayat EE, Ibrahim SA, Shoukry AA. Novel copper–phenothiazine–amino acid complexes exhibit selective anticancer activity via induction of apoptosis and cell cycle arrest in HepG2 cells. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05745-4
BibTeX
@article{Tamim2026,
author = {Tamim, Sally M and Zayat, Emad El and Ibrahim, Sherif Abdelaziz and Shoukry, Azza A},
title = {Novel copper–phenothiazine–amino acid complexes exhibit selective anticancer activity via induction of apoptosis and cell cycle arrest in HepG2 cells},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05745-4}
}
EUVIMED